Nigel Bernard John Clerkin Sells 2,267 Shares of Icon (NASDAQ:ICLR) Stock

Icon Plc (NASDAQ:ICLR) CFO Nigel Bernard John Clerkin sold 2,267 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $164.29, for a total transaction of $372,445.43. Following the transaction, the chief financial officer directly owned 5,881 shares of the company’s stock, valued at $966,189.49. The trade was a 27.82% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Icon Stock Performance

NASDAQ ICLR opened at $167.48 on Friday. The company has a market capitalization of $12.82 billion, a price-to-earnings ratio of 39.31, a PEG ratio of 6.93 and a beta of 1.21. The company has a quick ratio of 0.95, a current ratio of 0.95 and a debt-to-equity ratio of 0.23. Icon Plc has a twelve month low of $66.57 and a twelve month high of $203.91. The stock has a fifty day simple moving average of $162.22 and a 200 day simple moving average of $134.04.

Icon (NASDAQ:ICLR) last announced its earnings results on Thursday, July 30th. The medical research company reported $2.56 EPS for the quarter, topping the consensus estimate of $2.55 by $0.01. Icon had a return on equity of 8.02% and a net margin of 3.99%.The firm had revenue of $2.06 billion for the quarter, compared to the consensus estimate of $2 billion. During the same period in the previous year, the business earned $3.26 EPS. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. Sell-side analysts expect that Icon Plc will post 9.57 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Bank of America upped their price objective on shares of Icon from $125.00 to $150.00 and gave the company an “underperform” rating in a research note on Thursday, June 25th. TD Cowen boosted their target price on shares of Icon from $164.00 to $197.00 and gave the company a “buy” rating in a report on Thursday, June 25th. Piper Sandler cut shares of Icon to a “neutral” rating in a research report on Thursday, May 28th. Barclays increased their price target on Icon from $160.00 to $175.00 and gave the stock an “equal weight” rating in a report on Thursday, June 25th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $165.00 price objective on shares of Icon in a research note on Friday, May 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $170.40.

Key Headlines Impacting Icon

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Icon’s latest quarterly results modestly exceeded expectations: adjusted EPS was $2.56 versus the $2.55 consensus, while revenue of $2.06 billion topped estimates of $2.00 billion. Revenue also rose 2.3% year over year, indicating continued demand for its outsourced clinical-research services.
• Positive Sentiment: Analyst support remains a potential catalyst. BMO Capital Markets raised its price target to $187, Mizuho lifted its target to $190, and William Blair upgraded the stock to “strong buy.” The broader analyst consensus is “Hold,” with an average target of $170.40. Analyst coverage article
• Positive Sentiment: Institutional ownership is high at 95.61%, and several investment firms recently initiated or increased positions in ICLR. The stock is also trading above its 50-day and 200-day moving averages, reflecting favorable recent momentum.
• Neutral Sentiment: CEO Barry Balfe, CFO Nigel Clerkin and several directors sold shares totaling roughly $1.6 million at prices near $164.07–$164.29. The filings state that the sales were made to cover tax-withholding obligations connected with vested equity awards, and the insiders retained shares afterward, reducing the negative signal. Icon insider sales article
• Negative Sentiment: Although revenue beat estimates, quarterly EPS fell from $3.26 in the prior-year period, highlighting earnings pressure. ICLR also trades at a relatively demanding valuation, with a price-to-earnings ratio near 39 and a PEG ratio above 6, leaving the stock vulnerable if growth or guidance weakens.

Institutional Trading of Icon

Hedge funds have recently modified their holdings of the stock. Harris Associates L P acquired a new position in shares of Icon during the 2nd quarter valued at $238,256,000. Capital World Investors grew its holdings in Icon by 555.2% in the fourth quarter. Capital World Investors now owns 1,496,479 shares of the medical research company’s stock worth $272,688,000 after purchasing an additional 1,268,095 shares during the period. Wellington Management Group LLP increased its stake in Icon by 26.6% in the third quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock valued at $811,499,000 after purchasing an additional 975,268 shares in the last quarter. Lyrical Asset Management LP acquired a new position in shares of Icon during the fourth quarter valued at about $176,382,000. Finally, Norges Bank bought a new position in shares of Icon during the 4th quarter worth about $160,073,000. Institutional investors own 95.61% of the company’s stock.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.